As with every source you have attempted to cite, you didn't do your research.
A Case Series of Hydroxychloroquine Versus Control
In a case series from France, 26 hospitalized adults with SARS-CoV-2 infection categorized as asymptomatic or with upper or lower respiratory tract infection who received hydroxychloroquine 200 mg three times daily for 10 days were compared to 16 control individuals (i.e., who refused treatment, did not meet eligibility criteria, or were from a different clinic).13
Results:
- Six patients in the hydroxychloroquine group were excluded from the analysis for the following reasons:
- One patient died.
- Three patients were transferred to the ICU.
- One patient stopped taking the study drug due to nausea.
- One patient withdrew from the study.
- Six patients also received azithromycin.
- By Day 6, nasopharyngeal (NP) PCRs were negative in 14 of 20 (70%) hydroxychloroquine-treated patients and 2 of 16 (12.5%) controls.
- Among the hydroxychloroquine patients, 8 of 14 (57.1%) patients who received only hydroxychloroquine and 6 of 6 (100%) patients who received hydroxychloroquine and azithromycin had negative NP PCRs by Day 6.
- Clinical outcomes for all patients were not reported.
Limitations:
- There are several methodologic concerns with this case series:
- The sample size of the series is small.
- The criteria for enrollment of cases and controls is unclear.
- Asymptomatic individuals were enrolled.
- Exclusion of six hydroxychloroquine patients includes one death and three ICU transfers.
- No clinical outcomes were reported; thus, the clinical significance of a negative PCR is unknown.
- The reason for the addition of azithromycin for some patients is unclear.
Interpretation:
Methodologic problems with this case series limit the ability to draw conclusions regarding the efficacy of hydroxychloroquine with or without azithromycin.
https://covid19treatmentguidelines.nih.gov/antiviral-therapy/chloroquine-or-hydroxychloroquine/
Gautret had a lot of issues. And none of your sources are peer reviewed, though I suspect because of your background you don't understand why that is important in the science and medical community.
"To address the implications of this oversight, we re-analysed the control and hydroxychloroquine-treated patient data from Gautret et al. table 3, excluding the missing datasets noted above (see
table S1 in
appendix 1). There were no significant differences between the virological clearance rates of control and hydroxychloroquine-treated patients on treatment days 3, 4, 5, or 6 (
fig. 1A,
table S1). This is in stark contrast to the analysis of Gautret et al, analysis, which reported significant differences between the groups starting as early as day 3 and persisting until day 6."
https://smw.ch/article/doi/smw.2020.20262